NCT06068946CompletedPhase 2
VK2735 for Weight Management Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Source: ClinicalTrials.gov · Last updated 12 Feb 2025
Brief summary (registry, in English)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 176 (actual)
- First submitted
- 28 Sept 2023
- Start date
- 31 Aug 2023
- Primary completion date
- 27 Feb 2024
- Lead sponsor
- Viking Therapeutics, Inc.
- Diseases
- Obesity
- NCT number
- NCT06068946
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 176
- From 31 Aug 2023 to the primary completion date, 27 Feb 2024
- 20 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any prescription or over-the-counter medications intended for weight loss within 6 months of screening
Other illness
- History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation
- Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)
Lab values
- Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
Other
- Self-reported body weight change of 5% or more within 3 months of screening
- Current or past diagnosis of chronic pancreatitis
- Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening
Who the study is looking for
- Age ≥18 years of age at the time of signing the informed consent
- Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (20)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.Obesity (Silver Spring) · 2026 · PMID 41508550
This page is information, not medical advice. Discuss any trial with your doctor.